Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη της αγγειογένεσης σε ασθενείς με καρκίνο του ήπατος

Abstract

dc:description

Aim of this study was to evaluate the diagnostic and prognostic value of serum levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and Endostatin in patients with primary hepatocellular carcinoma (PHC) and in patients with metastatic liver disease (MLD). In this study were included twenty normal controls, thirty patients with PHC and thirty patients with MLD. Exclusion criteria were trauma, fracture, recent surgical treatment, history of recent myocardial infarction, malignant tumors to other organs except liver, rheumatoid arthritis, psoriatic arthritis, pregnancy, ovulation, chronic inflammations, inflammatory bowel disease, glaucoma and diabetic retinopathy. Blood samples were obtained from all the eighty participants, centrifuged and stored under special conditions. The concentrations of VEGF, bFGF and Endostatin in serum were measured by the quantitative sandwich immunoassay technique (sandwich ELIZA), using enzyme linked immunosorbent assay kits (R&D systems Inc., Minneapolis.MN). The results of this study are summarized as follows: 1) The mean serum levels of VEGF, bFGF and Endostatin in patients with PHC and in patients with MLD were significantly higher than the mean serum levels of VEGF, bFGF and Endostatin in normal controls. There was no significant difference between the mean serum levels of VEGF, bFGF and Endostatin in patients with PHC and in patients with MLD. 2) In patients with PHC there was a positive correlation between the serum level of VEGF and the serum level of a-fetoprotein (r=0.484, p=0.017), between the serum level of VEGF and tumor size (r=0.517, p=0.008), between the serum level of VEGF and the platelets number (r=0.573, p=0.003), between the tumor size and the serum level of a-fetoprotein (r=0.533, p=0.003) and between the tumor size and platelet count (r=0.510, p=0.005). 3) In patients with MLD there was a positive correlation between the serum level of VEGF and platelet count (r=0.388,p=0.05). 4) In patients with PHC the sensitivity of serum VEGF, bFGF and Endostatin was found 60%, 54% and 54% respectively. 5) In patients with MLD the sensitivity of serum VEGF, bFGF and Endostatin was found 73%, 73% and 61% respectively. 6) The specificity of serum VEGF, bFGF and Endostatin was found 95%, 95% and 100% respectively, in both of patients with PHC and with MLD. 7) The combined use of serum VEGF, bFGF and Endostatin increased the sensitivity of detection in patients with PHC and MLD. The conclusions of this study are summarized as follows: 1) The elevated concentrations of serum VEGF, bFGF and Endostatin in patients with liver cancer, indicates that the source of these angiogenic factors may be the tumor and reflects its angiogenic activity. 2) Serum VEGF, bFGF and Endostatin can distinguish normal controls from patients with liver cancer. 3) Serum VEGF, bFGF and Endostatin cannot distinguish patients with primary hepatocellular carcinoma from patients with metastatic liver disease. 4) Serum VEGF, bFGF and Endostatin could be useful tumor markers in the diagnosis of primary hepatocellular carcinoma and metastatic liver disease because of their high specificity. 5) The combined use of serum VEGF, bFGF and Endostatin increased the sensitivity of detection in patients liver cancer. 6) The measurment of serum levels of VEGF, bFGF and Endostatin is technically simple, cheap, non invasive method and repeated measurments can be made in the same patient. 7) The significant correlation of serum VEGF with a-fetoprotein and tumor size, both of which are prognostic markers in patients with primary hepatocellular carcinoma, indicates that serum VEGF may be useful as a new prognostic factor in patients with primary hepatocellular carcinoma. 8) The significant correlation of serum VEGF with platelet count in patients with liver cancer, suggests that the platelets have an important role in processes involving angiogenesis in liver cancer.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Νικοπούλου, Άννα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19576

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Νικοπούλου, Άννα. Μελέτη της αγγειογένεσης σε ασθενείς με καρκίνο του ήπατος. Aristotle University Of Thessaloniki (AUTH), 2008. http://hdl.handle.net/10442/hedi/19576